Differential treatment response to virtual reality in high-impact chronic pain: secondary analysis of a randomized trial
Abstract
High-impact chronic pain (HICP) affects 8.5% of the population and is associated with higher healthcare utilization and costs. Sparse data exist on pain treatment response differences between HICP vs. lower-impact chronic pain (LICP). We conducted a secondary analysis of a randomized controlled trial in a diverse community sample (N = 1067) with chronic low back pain who were demographically diverse (female: 77%; non-Caucasian: 32%; high school or less education: 19%; mean age: 50.8) and clinically severe (baseline pain intensity = 6.6, baseline pain interference = 6.2, and 42% severe/completely disabled). We compared HICP vs. LICP treatment responses for an 8-week Skills-Based Virtual Reality program at end-of-treatment and at 12-months for pain intensity and pain interference (multi-primary outcomes). MMRM analysis (multiplicity corrected) revealed significantly larger reductions (and clinically meaningful reductions) for HICP than LICP for both primary outcomes at both post-treatment time points. End-of-treatment reduction in pain interference among HICP reclassified 70% of them as LICP, and this improvement held at 12-months (67%). Significantly larger reductions were found for HICP vs LICP for the secondary outcomes Sleep Disturbance and the Oswestry Disability Index, but not for Depression. No differences were found for HICP vs. LICP for device engagement or usability scores. Trial registration: ClinicalTrials.govNCT05263037.
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,067 participants or records.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.